Skip to main content
Caplight Logo









Perha Pharmaceuticals

Perha Pharmaceuticals

Private
RoscoffHealthcare & Life Scienceshttps://www.perha-pharma.com/

Last Round

Grant

Mar 23, 2022

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Perha Pharmaceuticals is a biotechnology company that develops small-molecule kinase inhibitors derived from natural marine products for the treatment of cognitive disorders and the prevention of hearing loss.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverykinase inhibitorDYRK1Asmall-molecule drugneurodegenerative diseasemarine-derived drugspreclinical researchDown syndromeAlzheimer's diseasedrug pipelinebiotech startupototoxicitydrug licensingtherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Perha Pharmaceuticals Comparables

Compare Perha Pharmaceuticals with similar companies based on industry and business-model similarity.

Perha Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pharmasum Therapeutics
89%
Iluminos Therapeutics LLC
81%
Connecta Therapeutics
79%

Perha Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 23, 2022
VC RoundMar 23, 2022

Perha Pharmaceuticals Investors

Notable investors and investment history

Perha Pharmaceuticals investors
InvestorRounds
European Innovation Council FundGrant, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors grew 149% MoM, from 431 to 1.1K.

  • Apr 16, 2026

    Monthly visitors increased 53% MoM.

Perha Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Perha Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Perha Pharmaceuticals's valuation, stock price, and market status.

Is Perha Pharmaceuticals a public or private company?

Perha Pharmaceuticals is a private company.

What is the current stock price of Perha Pharmaceuticals?

Perha Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.

How much is Perha Pharmaceuticals worth (valuation)?

Valuation information for Perha Pharmaceuticals is not publicly available.

Can I buy Perha Pharmaceuticals stock?

Perha Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Perha Pharmaceuticals's last funding round?

Perha Pharmaceuticals's most recent funding round was Grant on March 23, 2022.

Who are the main investors in Perha Pharmaceuticals?

Key investors in Perha Pharmaceuticals include European Innovation Council Fund.

Will Perha Pharmaceuticals IPO soon?

No public IPO plans have been announced for Perha Pharmaceuticals.

How can I track Perha Pharmaceuticals secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Perha Pharmaceuticals's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersRoscoff
Employee Range12
Year Founded2019
Last FundingMar 23, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?